• 1
    Glennie MJ, Johnson PWM. Clinical trials of antibody therapy. Immunol Today 2000; 21: 40310.
  • 2
    Schubiger PA, Alberto R, Smith A. Vehicles, chelators, and radionuclides: choosing the building blocks of an effective therapeutic radioimmunoconjugate. Bioconj Chem 1996; 7: 16579.
  • 3
    Závada J, Závadová Z, Pastoreková S, Čiampor F, Pastorek J, Zelník V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993; 54: 26874.
  • 4
    Liao SY, Brewer C, Závada J, Pastorek J, Pastoreková S, Manetta A, Bermann ML, DiSaia PJ, Stanbridge EJ. Identification of MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994; 145: 598609.
  • 5
    Vermylen P, Roufosse C, Burny A, Verhest A, Bosschaerts T, Pastorekova S, Ninane V, Sculier JP. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J 1999; 14: 80611.
  • 6
    Wykoff CC, Beasley NJP, Watson PH, Campo L, Chia SK, English R, Pastorek J, Sly WS, Ratcliffe P, Harris AL. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 2001; 158: 10119.
  • 7
    Liao, SY, Aurelio ON, Jan K, Závada J, Stanbridge EJ. Identification of MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of kidney. Cancer Res 1997; 57: 282731.
  • 8
    Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, Kairaluoma MI, Karttunen TJ. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 1998; 153: 27985.
  • 9
    Pastoreková S, Parkkila S, Parkkila AK, Opavský R, Zelník V, Saarnio J, Pastorek J. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementery DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997; 112: 398408.
  • 10
    Wykoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. Hypoxia inducible regulation of tumor associated carbonic anhydrases. Cancer Res 2000; 60: 707583.
  • 11
    Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wykoff CC, Pastorek J, Ratcliffe PJ, West CML. CA IX expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 63949.
  • 12
    Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 52627.
  • 13
    Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7: 3399403.
  • 14
    Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 450915.
  • 15
    Ivanov SV, Kuzmin I, Wie MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A 1998; 95: 12596601.
  • 16
    Závada J, Závadová Z, Pastorek J, Biesová Z, Jezek K, Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82: 180813.
  • 17
    Pastoreková S, Závadová Z, Koštál M, Babušíková O, Závada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187: 6206.
  • 18
    Pastorek J, Pastoreková S, Callebaut I, Mornon JP, Zelník V, Opavský R, Zaltovičová M, Liao SY, Portetelle D, Stanbridge EJ, Závada J, Burny A, et al. Cloning and characterization of MN. A human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9: 287788.
  • 19
    Opavský R, Pastoreková S, Zelník V, Gibadulinová A, Stanbridge EJ, Závada J, Kettmann R, Pastorek J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationship. Genomics 1996; 33: 4807.
  • 20
    Bystrická M, Vancikova M, Kasalová M, Russ G, Rajcani J, Koštál M, Poláková K. Type-common and type-specific monoclonal antibodies to Herpes simplex virus type 1 and 2. Acta Virol 1991; 35: 15264.
  • 21
    Hunter WM. Radioimmunoassay. In: WeirDM, ed. Handbook of experimental immunology. Oxford: Blackwell, 1978. 14.1.40.
  • 22
    Lindmo T, Boven E, Cuttitta F, Feorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinity antigen excess. J Immunol Methods 1984; 72: 7789.
  • 23
    Yamaoka K, Tanigawara Y. Statistical moments: pharmacokinetics using personal computer. Tokyo: Nankoh-doh Press, 1983. 11339.
  • 24
    Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion AIC in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 16575.
  • 25
    Lieskovská J, Opavský R, Žáčiková L, Glasová M, Pastorek J, Pastoreková S. Study of in vitro conditions modulating expression of MN/CA IX protein in human cell lines derived from cervical carcinoma. Neoplasma 1999; 46: 1724.
  • 26
    Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastoreková S, Pastorek J, Sly SW. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A 2000; 97: 22204.
  • 27
    Kaluz S, Kaluzová M, Chrastina A, Olive PL, Pastoreková S, Pastorek J, Lerman MI, Stanbridge EJ. Lowered oxygen tension induces expression of the hypoxia marker MN/CA IX in the absence of HIF-1α stabilization: a role for PI3-K. Cancer Res, 2002; 62: 446977.
  • 28
    Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6: 15762.
  • 29
    Jain RK, Baxter LT. Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48: 702232.
  • 30
    Durbin PW, Jeung N, Kullgren B, Clemons GK. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys 1992; 63: 42742.
  • 31
    Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158: 90519.
  • 32
    Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 48994.
  • 33
    Grabmaier K, Vissers JLM, De Weijert MCA, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000; 85: 86570.
  • 34
    van Dijk J, Uemura H, Beniers AJMC, Peelen WP, Zegveld ST, Fleuren GJ, Warnaar SO, Oosterwijk E. Therapeutic effects of monoclonal antibody G250, interferons and tumor-necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994; 56: 2628.
  • 35
    Oosterwijk E, Debruyne FM, Schalken JA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 1995; 22: 3441.
  • 36
    Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 152937.
  • 37
    Kranenborg MH, Boerman OC, Oosterwijk-Wakka JC, de Weijert MC, Corstens FH, Oosterwijk E. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma x anti-DTPA bispecific monoclonal antibodies. Int J Cancer 1998; 75: 7480.
  • 38
    Steffens MG, Boerman OC, DeMulder PHM, Oyen WJG, Buijs WCAM, Witjes JA, van der Broek WJ, Oosterwijk-Wakka CJ, Debruyne FM, Corstens FH, Oosterwijk E. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5 (10 Suppl): 3268s74s.
  • 39
    Pimm MV, Baldwin RW. Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities. Eur J Nucl Med 1987; 13: 34852.
  • 40
    Strand SE, Norrgren K, Garkavij M, Lindgren L, Nilsson R, Sjogren HO, Tennvall J. A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio. Cancer 1994; 73 (Suppl): 10337.
  • 41
    Wu AM. Tools for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 2001; 16: 1038.
  • 42
    Pressman D. The development and use of radiolabeled antitumor antibodies. Cancer Res 1980; 40: 29604.
  • 43
    McKiernan JM, Buttyan R, Bander NH, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 1999; 86: 4927.
  • 44
    King DJ, Antoniw P, Owens RRJ, Adair JR, Haines AMR, Farnsworth APH, Finney H, Lawson DG, Lyons A, Baker TS, Baldock D, Mackintosh J, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer 1995; 72: 136472.
  • 45
    Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 1993; 34: 172838.
  • 46
    Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID. Comparative metabolism and retention of iodine-125, yttrium-90 and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56: 21239.
  • 47
    Horsman MR. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998; 42: 7014.
  • 48
    Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61: 79928.